Roger Meurer
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Asthma and respiratory diseases, Cell Adhesion Molecules Research, Peroxisome Proliferator-Activated Receptors, Cholesterol and Lipid Metabolism, Drug Transport and Resistance Mechanisms
Most-Cited Works
- → L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor(1989)328 cited
- → Peroxisome Proliferator-Activated Receptors γ and α Mediate in Vivo Regulation of Uncoupling Protein (UCP-1, UCP-2, UCP-3) Gene Expression(1998)272 cited
- → Formation of eosinophilic and monocytic intradermal inflammatory sites in the dog by injection of human RANTES but not human monocyte chemoattractant protein 1, human macrophage inflammatory protein 1 alpha, or human interleukin 8.(1993)171 cited
- → Characterization and species distribution of high affinity GTP-coupled receptors for human rantes and monocyte chemoattractant protein 1.(1993)83 cited
- → Substituted 2-aminopyridines as inhibitors of nitric oxide synthases(2000)47 cited
- → Altered lipoprotein metabolism in P2Y13 knockout mice(2010)39 cited
- → MK-0767, a novel dual PPARα/γ agonist, displays robust antihyperglycemic and hypolipidemic activities(2004)33 cited
- → L-656,224 (7-chloro-2-[(4-methoxyphenyl)methyl]-3-methyl-5-propyl-4-benzofuranol): a novel, selective, orally active 5-lipoxygenase inhibitor(1987)30 cited
- → ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose(2010)29 cited
- → Effects of cyclooxygenase and lipoxygenase inhibitors on inflammation associated with oxazolone-induced delayed hypersensitivity(1988)26 cited